- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 14
- States / cities
- Springdale, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autoimmune Encephalitis (AE)
- Interventions
- Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Sherman, Texas
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus
- Interventions
- efgartigimod PH20 SC, prednisone
- Biological · Drug
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 13 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 21 more
- Conditions
- Bullous Pemphigoid
- Interventions
- efgartigimod PH20 SC, Prednisone
- Biological · Drug
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 3 more
- Conditions
- Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
- Interventions
- Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Bentonville, Arkansas • Washington D.C., District of Columbia • Fort Wayne, Indiana + 2 more